

REMARKS

Restriction Requirement

In response to the Restriction Requirement, applicants elect claims 16, 17, and 23 of Group III. It is respectfully asserted to the Examiner that a Preliminary Amendment was included in the new application transmittal papers upon filing the subject application, in which claims 1-15 and 18-22 were canceled. Therefore, only claims 16, 17, and 23 are pending in the subject application and claims 16, 17, and 23 are elected to continue prosecution in the subject application.

Sequence Listing

Also in the Restriction Requirement mailed September 23, 2003, the Examiner required that a Sequence Listing be filed. A Sequence Listing in accordance with the requirements of 37 C.F.R. 1.821-8.825 is included herewith.

A co-pending U.S. application Serial No. 09/910,071 by the applicant of the above-mentioned '809 application includes the same sequence listing as presented herewith.

In accordance with 37 C.F.R. 1.821(e), it is respectfully requested that the computer-readable format of the Sequence Listing filed in the '071 application February 19, 2002 be used in lieu of filing a new computer-readable form in the present '809 application. The filing of the computer-readable format of the Sequence Listing in the '071 application was discussed with Examiner Zhou by telephone conference on January 22, 2004.

Included herewith are:

(A) a paper copy of a Sequence Listing entitled "sequence2.ST25" generated using PatentIn version 3.1 in February 2002 and corresponding to the sequences included in the '071 application and in the '809 application (with modifications of numeric identifiers <130>, <140>, and <170> to refer to the '809 application instead of the '071 application and to creating the sequence listing in the '071 application). These modifications were discussed with Examiner Zhou via telephone conference on January 22, 2004.

(B) Statements Regarding Sequence Listings, including a request to use the computer-readable format filed in the '071 application in lieu of filing a new computer-readable

format;

(C) Replacement Figures indicating the Sequence ID numbers, as discussed herein above, including Figures 10-12, 23A, 23B, 25, 26, 29, 30, 38A, 38B, 39A, 39B, and 46.

Entry of (A) - (C), above, and advancement of the subject application to examination are respectfully requested.

An Information Disclosure Statement is filed concurrently herewith.

If any further fees are required in connection with the filing of this paper, please charge our Deposit Account No. 19-3935.


Respectfully submitted,

STAAS & HALSEY LLP

Date:

Aug 23, 2004

By:



Gene M. Garner II
Registration No. 34,172

700 Eleventh Street, NW, Suite 500
Washington, D.C. 20001
(202) 434-1500